Regen BioPharma Inc

OTCPK:RGBP

États-Unis / Santé / Biotechnologie

Aperçu

Actualités

Historique des finances 5 ans

Prix Action

0,05 USD


Key Metrics	Latest
Total Revenue	236,56 K
Adjusted EBITDA	-418,189 K
EBITDA Margin	-176,8%
Net Profit Margin	-302,5%
Total Assets	177,611 K
Total Debt	794,699 K

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Sep-20	Sep-21	Sep-22	Sep-23	Sep-24	12 Months	Sep-23	Sep-24

Revenue	0.11	0.17	0.24	0.24	0.24	0.24	0.24	0.24
% Growth		0.56	0.38	0.00	0.00			0.00

Adjusted EBITDA	(0.21)	(0.20)	(0.34)	(0.69)	(0.42)	(0.42)	(0.69)	(0.42)
% Margin	(1.90)	(1.17)	(1.44)	(2.90)	(1.77)	(1.77)	(2.90)	(1.77)

Adjusted EBIT	(0.21)	(0.20)	(0.34)	(0.69)	(0.42)	(0.42)	(0.69)	(0.42)
% Margin	(1.90)	(1.17)	(1.44)	(2.90)	(1.77)	(1.77)	(2.90)	(1.77)

Adjusted Net Income	3.41	(5.34)	2.45	1.16	(0.72)	(0.72)	1.16	(0.72)
% Margin	31.04	(31.16)	10.38	4.89	(3.03)	(3.03)	4.89	(3.03)

Adjusted Basic EPS	1.82	(1.33)	0.39	0.16	(0.09)	(0.09)	0.16	(0.09)

Calculs d'appui

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Sep-20	Sep-21	Sep-22	Sep-23	Sep-24	Sep-24	Sep-23	Sep-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	0	0	0	0	0	0	0	0
% Growth	NA	55.6%	37.6%	0.4%	0.0%			0.0%

Cost of Revenue	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0
% Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Research and Development	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(0)	(0)	(0)	(1)	(1)	(1)	(1)	(1)
Other Inc / (Exp)	5	(6)	3	2	(0)	(0)	2	(0)
Total Operating Exp	4	(7)	2	1	(1)	(1)	1	(1)

Operating Income	4	(6)	3	1	(1)	(1)	1	(1)
% Revenue	3961.2%	-3737.5%	1126.4%	514.0%	-323.7%	-323.7%	514.0%	-323.7%

Interest Expense	(1)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Pre-tax Income	3	(7)	2	1	(1)	(1)	1	(1)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0
Net Income to Company	3	(7)	2	1	(1)	(1)	1	(1)
% Margin	3104.0%	-3951.8%	1037.5%	488.9%	-366.6%	-366.6%	488.9%	-366.6%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	3	(7)	2	1	(1)	(1)	1	(1)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	(0)	(0)	0	0	(0)	0

Net Income to Common	3	(7)	2	1	(1)	(1)	1	(1)
% Margin	3104.0%	-3951.8%	945.6%	432.7%	-366.6%	-366.6%	432.7%	-366.6%

As Reported
Basic EPS (Continuing Ops)	1.82	(1.68)	0.36	0.14	(0.11)	(0.11)	0.14	(0.11)
Diluted EPS (Continuing Ops)	1.82	(1.68)	0.36	0.14	(0.11)	(0.11)	0.14	(0.11)

WA Basic Shares Out.	1.88	4.02	6.27	7.07	8.22	8.22	7.07	8.22
WA Diluted Shares Out.	1.88	4.02	6.27	7.07	8.22	8.22	7.07	8.22

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	3	(7)	2	1	(1)	(1)	1	(1)
Addback: Net Interest Expense	1	0	0	0	0	0	0	0
Addback: Other Non Operating Expenses, Total	(5)	4	(3)	(2)	0	0	(2)	0
Addback: Depreciation & Amortization	0	0	0	0	0	0	0	0
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	1	(0)	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	1	0	0	0	0	0	0
Addback: Other Unusual Items	0	(0)	0	(0)	0	0	(0)	0
Adjusted EBITDA	(0)	(0)	(0)	(1)	(0)	(0)	(1)	(0)
% Margin	-190.3%	-117.3%	-144.2%	-290.4%	-176.8%	-176.8%	-290.4%	-176.8%

Adjusted EBIT	(0)	(0)	(0)	(1)	(0)	(0)	(1)	(0)
% Margin	-190.3%	-117.3%	-144.2%	-290.4%	-176.8%	-176.8%	-290.4%	-176.8%

Adjusted Net Income Reconciliation
Net Income to Company	3	(7)	2	1	(1)	(1)	1	(1)
Addback: Unusual Items	0	2	0	(0)	0	0	(0)	0
Less: Tax Benefit of Unusual Items (26%)	0	(1)	(0)	0	(0)	(0)	0	(0)
Adjusted Net Income	3	(5)	2	1	(1)	(1)	1	(1)
% Margin	3104.0%	-3116.4%	1038.4%	488.5%	-302.5%	-302.5%	488.5%	-302.5%

Erreur de Chargement

Regen BioPharma Inc

OTCPK:RGBP

États-Unis / Santé / Biotechnologie

Historique des finances 5 ans